Cargando…
Review time of oncology drugs and its underlying factors: an exploration in China
Introduction: How the launch delay of drugs and other factors of interest can influence the length of the review period by drug agencies is still unknown, and understanding this can help better strike the trade-off related to review speed. Methods: We included all new oncology drug applications subm...
Autores principales: | Zhu, Xingyue, Liu, Bao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654631/ https://www.ncbi.nlm.nih.gov/pubmed/38027001 http://dx.doi.org/10.3389/fphar.2023.1151784 |
Ejemplares similares
-
The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023) -
Lychee Seed as a Potential Hypoglycemic Agent, and Exploration of its Underlying Mechanisms
por: Zhang, Yuehong, et al.
Publicado: (2021) -
Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016) -
“Hard” Drug Repurposing for Precision Oncology: The Missing Link?
por: Pantziarka, Pan, et al.
Publicado: (2018) -
A Database of Drug Repurposing Clinical Trials in Oncology
por: Pantziarka, Pan, et al.
Publicado: (2021)